Celcuity
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 55
- Market Cap
- -
- Introduction
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Conditions
- Breast Cancer
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 674
- Registration Number
- NCT06757634
- Locations
- πΊπΈ
Providence Medical Foundation, Fullerton, California, United States
πΊπΈUCLA Hematology Oncology Ventura, Los Angeles, California, United States
πΊπΈThe University of Kansas Cancer Center, Westwood, Kansas, United States
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer)Genital Diseases, MaleProstatic DiseaseProstatic Neoplasms, Castration-ResistantUrogenital Diseases, MaleProstate Cancer
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 54
- Registration Number
- NCT06190899
- Locations
- πΊπΈ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
π«π·Centre Jean Perrin, Clermont-Ferrand, France
π«π·Institut Paoli-Calmettes, Marseille, France
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 701
- Registration Number
- NCT05501886
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈArizona Oncology (US Oncology/McKesson) - Goodyear, Goodyear, Arizona, United States
πΊπΈSt. Bernards Medical Center, Jonesboro, Arkansas, United States
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
- Conditions
- Breast Neoplasm Malignant Female
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Celcuity Inc
- Registration Number
- NCT05134922
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
πΊπΈOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02684032
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCompassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States
πΊπΈKeck Hospital of USC - Norris Healthcare Center (HC3), Los Angeles, California, United States